BRPI0615384B8 - composições oftálmicas de cetotifeno estabilizadas e conservadas - Google Patents

composições oftálmicas de cetotifeno estabilizadas e conservadas

Info

Publication number
BRPI0615384B8
BRPI0615384B8 BRPI0615384A BRPI0615384A BRPI0615384B8 BR PI0615384 B8 BRPI0615384 B8 BR PI0615384B8 BR PI0615384 A BRPI0615384 A BR PI0615384A BR PI0615384 A BRPI0615384 A BR PI0615384A BR PI0615384 B8 BRPI0615384 B8 BR PI0615384B8
Authority
BR
Brazil
Prior art keywords
ophthalmic compositions
stabilized
hydrogen peroxide
preserved
ketotifen ophthalmic
Prior art date
Application number
BRPI0615384A
Other languages
English (en)
Inventor
Tsao Fu-Pao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0615384A2 publication Critical patent/BRPI0615384A2/pt
Publication of BRPI0615384B1 publication Critical patent/BRPI0615384B1/pt
Publication of BRPI0615384B8 publication Critical patent/BRPI0615384B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

composições oftálmicas de cetotifeno estabilizadas e conservadas. a presente invenção refere-se a composições oftálmicas que compreendem cetotifeno, uma fonte de peróxido de hidrogênio que fornece uma quantidade de peróxido de hidro-gênio de desde aproximadamente 0,001 até aproximadamente 0,1% (peso/volume), um ou mais estabilizadores de peróxido de hidrogênio oculares-compatíveis, hpmc e cmc, e processos para o tratamento e a prevenção de conjuntivite alérgica usando estas compo-sições oftálmicas.
BRPI0615384A 2005-08-26 2006-08-24 composições oftálmicas de cetotifeno estabilizadas e conservadas BRPI0615384B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/212,957 2005-08-26
US11/212,957 US20070048388A1 (en) 2005-08-26 2005-08-26 Stabilized and preserved ketotifen ophthalmic compositions
PCT/US2006/033163 WO2007025094A2 (en) 2005-08-26 2006-08-24 Stabilized and preserved ketotifen ophthalmic compositions

Publications (3)

Publication Number Publication Date
BRPI0615384A2 BRPI0615384A2 (pt) 2011-05-17
BRPI0615384B1 BRPI0615384B1 (pt) 2019-06-18
BRPI0615384B8 true BRPI0615384B8 (pt) 2021-05-25

Family

ID=37670685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615384A BRPI0615384B8 (pt) 2005-08-26 2006-08-24 composições oftálmicas de cetotifeno estabilizadas e conservadas

Country Status (19)

Country Link
US (4) US20070048388A1 (pt)
EP (1) EP1926472B1 (pt)
JP (1) JP5172678B2 (pt)
KR (1) KR20080042143A (pt)
CN (1) CN101252908B (pt)
AT (1) ATE505182T1 (pt)
AU (2) AU2006282980A1 (pt)
BR (1) BRPI0615384B8 (pt)
CA (1) CA2619834C (pt)
CY (1) CY1111678T1 (pt)
DE (1) DE602006021321D1 (pt)
DK (1) DK1926472T3 (pt)
ES (1) ES2363988T3 (pt)
MX (1) MX2008002653A (pt)
PL (1) PL1926472T3 (pt)
PT (1) PT1926472E (pt)
RU (1) RU2442583C2 (pt)
SI (1) SI1926472T1 (pt)
WO (1) WO2007025094A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20090220618A1 (en) * 2008-02-29 2009-09-03 Erning Xia Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide
AU2010226249A1 (en) * 2009-03-17 2011-10-13 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
CN110024781A (zh) * 2019-05-23 2019-07-19 昆明野水生物科技有限公司 一种在常温下能迅速杀灭芽孢的制剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614646A (en) * 1984-12-24 1986-09-30 The Dow Chemical Company Stabilization of peroxide systems in the presence of alkaline earth metal ions
US4819617A (en) * 1986-09-04 1989-04-11 University Of Florida Viscoelastic material for ophthalmic surgery
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
IL91131A (en) * 1988-08-04 1993-06-10 Ciba Geigy Ag Method of preserving ophthalmic solutions using a hydrogen peroxide source and compositions therefor
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
WO2000019981A1 (en) * 1998-10-08 2000-04-13 Karagoezian Hampar L Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide
GB9824160D0 (en) * 1998-11-04 1998-12-30 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
RU2266115C2 (ru) * 1999-09-13 2005-12-20 Бридж Фарма, Инк. Оптически активные изомеры кетотифена и их терапевтически активные метаболиты
US6531128B1 (en) * 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
CA2404226A1 (en) * 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
JP2004509925A (ja) * 2000-09-28 2004-04-02 ノバルティス　アクチエンゲゼルシャフト 安定化過酸化水素溶液
RU2193403C1 (ru) * 2001-05-23 2002-11-27 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Глазные капли для лечения аллергических конъюнктивитов и кератоконъюнктивитов
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
US20070092582A1 (en) * 2002-01-18 2007-04-26 Fu-Pao Tsao Methods of preserving ophthalmic solutions and preserved ophthalmic solutions
JP2004143157A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 点眼剤
US20050244509A1 (en) * 2004-03-17 2005-11-03 Fu-Pao Tsao Ophthalmic solutions

Also Published As

Publication number Publication date
BRPI0615384A2 (pt) 2011-05-17
US20080193558A1 (en) 2008-08-14
CN101252908B (zh) 2011-09-14
CA2619834A1 (en) 2007-03-01
US20130102634A1 (en) 2013-04-25
JP5172678B2 (ja) 2013-03-27
CN101252908A (zh) 2008-08-27
AU2010241211B2 (en) 2012-12-20
RU2008111067A (ru) 2009-10-10
PL1926472T3 (pl) 2011-09-30
RU2442583C2 (ru) 2012-02-20
AU2010241211A1 (en) 2010-11-25
JP2009506065A (ja) 2009-02-12
ATE505182T1 (de) 2011-04-15
WO2007025094A2 (en) 2007-03-01
US20070048388A1 (en) 2007-03-01
BRPI0615384B1 (pt) 2019-06-18
US20120095050A1 (en) 2012-04-19
EP1926472B1 (en) 2011-04-13
PT1926472E (pt) 2011-07-11
EP1926472A2 (en) 2008-06-04
KR20080042143A (ko) 2008-05-14
DK1926472T3 (da) 2011-07-18
WO2007025094A3 (en) 2007-05-18
ES2363988T3 (es) 2011-08-22
AU2006282980A1 (en) 2007-03-01
SI1926472T1 (sl) 2011-07-29
CY1111678T1 (el) 2015-10-07
CA2619834C (en) 2014-05-06
DE602006021321D1 (de) 2011-05-26
MX2008002653A (es) 2008-03-18

Similar Documents

Publication Publication Date Title
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
DK1819353T3 (da) Sammensætning til proteasomhæmning
PE20081506A1 (es) Formulaciones de ansamicina
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
MX2009003821A (es) Compuestos de n-aril pirazol para usarse contra la diabetes.
EA201170703A1 (ru) Производные адамантилбензамида
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
NO20081160L (no) Benzimidazoltiofen forbindelser
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20076515L (no) Hydantoinforbindelser
TW200740799A (en) Alpha2C adrenoreceptor agonists
TNSN07240A1 (en) Compounds for flaviviridae treatment
NO20082298L (no) Kaliumkanalinhibitorer
TN2010000074A1 (en) Cyclic depsipeptides
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
CY1111678T1 (el) Σταθεροποιημενες και διατηρημενες οφθαλμικες ενωσεις κετοτιφενης
DE60317935D1 (de) Alpha-aminoamid-derivate als mittel gegen migräne

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF